FTC’s “Authorized” Generics Study Should Have Greater “Qualitative” Focus, GPhA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
PhRMA, however, contends FTC’s information collection proposal “lacks practical utility” and instead should include more quantitative data.